Chembio Diagnostics (CEMI) Appoints Leslie Teso-Lichtman to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors
May 24, 2022 4:15 PM EDTHAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Directors at Chembios 2022 Annual Meeting of Stockholders.
We are excited to have Leslie join the Chembio Board of Directors, said Richard Eberly, Chembios Chief Executive Officer and President. Her significant experience in corporate financial leadership at global diagnostics companies will be an important asset as we strive to create value through our Global Competitiveness program by leveraging Chembios broad product portfolio and operations worldwide.
Ms.... More
